OncoZenge
Phase 3OncoZenge is developing a lozenge that will help millions of people with their oral pain. Our primary indication is oral mucositis, a painful side effect from radiotherapy and chemotherapy.
Founded
2015
Focus
OncologyDrug Delivery
About
OncoZenge is developing a lozenge that will help millions of people with their oral pain. Our primary indication is oral mucositis, a painful side effect from radiotherapy and chemotherapy.
Funding History
2Total raised: $10.5M
Series A$8MKTH HoldingDec 15, 2022
Seed$2.5MKTH HoldingJun 15, 2021
Company Info
TypePrivate
Founded2015
LocationStockholm, Sweden
StagePhase 3
Contact
SIMILAR COMPANIES
Basic Genomics
Pre-clinical · Stockholm
2A Pharma
Phase 1 · Stockholm
Abliva
Pre-clinical · Lund
Affibody
Phase 1 · Solna
Alligator Bioscience
Phase 1 · Lund
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile